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The Key Regulatory Roles of the PI3K/Akt Signaling
Pathway in the Functionalities of Mesenchymal
Stem Cells and Applications in Tissue Regeneration
Jiezhong Chen, PhD,1–3 Ross Crawford, PhD,1 Chen Chen, PhD,2 and Yin Xiao, PhD1
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into various cell types and have been
widely used in tissue engineering application. In tissue engineering, a scaffold, MSCs and growth factors are
used as essential components and their interactions have been regarded to be important for regeneration of
tissues. A critical problem for MSCs in tissue engineering is their low survival ability and functionality. Most
MSCs are going to be apoptotic after transplantation. Therefore, increasing MSC survival ability and func-
tionalities is the key for potential applications of MSCs. Several approaches have been studied to increase MSC
tissue forming capacity including application of growth factors, overexpression of stem cell regulatory genes,
and improvement of biomaterials for scaffolds. The effects of these approaches on MSCs have been associated
with activation of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. The pathway plays central
regulatory roles in MSC survival, proliferation, migration, angiogenesis, cytokine production, and differentia-
tion. In this review, we summarize and discuss the literatures related to the roles of the PI3K/Akt pathway in the
functionalities of MSCs and the involvement of the pathway in biomaterials-increased MSC functionalities.
Biomaterials have been modified in their properties and surface structure and loaded with growth factors to
increase MSC functionalities. Several studies demonstrated that the biomaterials-increased MSC functionalities
are mediated by the activation of the PI3K/Akt pathway.
Introduction
Mesenchymal stem cells (MSCs) are multipotent stemcells with the ability to self-renew and differentiate
into many types of mature cells.1–5 A recent study showed
that MSCs can be expanded for more than 50 passages in cell
culure.6 MSCs have a fibroblast-like morphology and express
stromal markers, including CD73, CD105, CD29, CD44, and
CD90, but not hematopoietic markers.7,8 MSCs can develop
into many different types of tissues such as bone, cartilage,
fat, tendon, muscle, marrow stroma, nerve, and liver.9,10
Therefore, these cells are widely applied in regenerative
medicine, for examples, bone tissue engineering application,
in which MSCs are implanted in a scaffold to regenerate new
tissues.1,2,11–13 Growth factors are usually added to the sys-
tem to strengthen MSC functionality.14,15 Although embry-
onic stem (ES) cells have a much higher capacity to
differentiate into many cell types,16–18 there are several ad-
vantages to use MSCs rather than ES cells in addition to the
ethical issues. First, ES cells have the potential to cause
cancer such as teratoma, an encapsulated tumor with dif-
ferent organs such as hair, eye, teeth, and bone, and they are
much more difficult to control in vivo than MSCs.19 Second,
MSCs are easier to obtain from the bone marrow or other
tissues such as adipose tissue and umbilical cord blood.
Third, MSCs have the immunomodulatory effect to decrease
transplantation rejection.20 Except tissue engineering appli-
cation, MSCs have also been used alone for cellular therapy
to repair damaged tissues.21,22 Systemically administered
MSCs have been demonstrated to be able to travel to injured
tissues and improve tissue regeneration such as heart, brain,
renal, and skeletal tissues.23–27 Preliminary clinical trials of
MSCs for the treatment of myocardial ischemia and osteo-
genesis imperfecta have been performed and showed mod-
erate beneficial effects.28–31 The knowledge obtained from
extensive studies of MSCs in cellular therapy could be ap-
plicable for tissue engineering.
Although MSCs were discovered from bone marrow
(BMSCs), they have also been isolated from other tissues,
including adipose tissue, umbilical cord blood, placenta,
dental pulp, and pancreatic islets.32–36 All these MSCs have
similar molecular markers with positive expression of mes-
enchymal markers (CD90, CD29, CD44, and CD105) and lack
of CD34, CD45, CD11b, and HLA-DR.36,37 MSCs from
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adipose tissue (ASCs) are extensively studied to substitute
BMSCs with several obvious advantages. First, the adipose
tissues are easier to obtain than bone marrow. Second, MSCs
in adipose tissue are much more abundant than that in bone
marrow. Third, ASCs have higher ability to proliferate than
BMSCs.37
A major problem in the application of MSCs is that the
differentiation capability of MSCs is decreased in the trans-
planted environment.38 This decrease could be due to the
new extracellular microenvironment, which is different from
the natural environment of MSCs and is hostile to these cells.
Therefore, most MSCs cannot survive long enough to gen-
erate terminally differentiated cells after transplantation.38
For example, 90% of MSCs were shown to be apoptotic, a
programmed cell death, within 3 days after transplantation
into heart for cardiomyocyte infarct repair.39,40 However,
cellular therapy using MSCs is still effective to a certain ex-
tent. The beneficial effects of MSCs are thought to be medi-
ated by cytokines produced by MSCs rather than new tissues
formed from MSCs.39,41 This may also be the case in tissue
engineering. Therefore, there is room to further improve the
efficacy of MSC-based treatments by increasing the survival
ability and functionality of MSCs in the transplantation en-
vironment.
Many different approaches have been used to stimulate
MSC proliferation and differentiation and to promote long-
term survival and functionalities. These approaches include
the delivery of bioactive materials or proteins,42 the over-
expression of genes in MSCs such as vascular endothelial
growth factor (VEGF), Protein kinase B (Akt), bcl-2,43–48 and
the improvement of biomaterials used for scaffolds.49 Inter-
estingly, all above approaches are involved in an intracellu-
lar signal pathway, phosphoinositide 3-kinase/Akt (PI3K/
Akt). In this review, we will summarize the roles of the
PI3K/Akt pathway in the functionalities of MSCs, how
biomaterials affect MSC functionalities via the activation of
the PI3K/Akt pathway, and discuss possible implications.
The PI3K/Akt Pathway in MSCs
Overview of the PI3K/Akt pathway
The PI3K/Akt pathway is a survival pathway that regu-
lates cell proliferation, apoptosis, differentiation, and migra-
tion.50 The upstream stimulators of the pathway include
various growth hormones, cytokines, and foreign molecules.
The PI3K/Akt pathway has been shown to play key roles in
the physiology and pathophysiology of many types of cells.51–54
Abnormal increase or decrease in the PI3K/Akt pathway ac-
tivity is associated with many diseases such as cancer, dia-
betes, laminopathy, stroke, and neurodegenerative diseases
and manipulation of the pathway has been proposed for the
treatment of these diseases.50 The PI3K/Akt also plays a key
role in regulating neuronal function through protein ataxin-1,
GABA receptor, and disruption of the pathway is associated
with diseases such as Huntingtin disease.55
The key enzyme of the pathway, PI3K, converts phos-
phatidylinositol 4,5-biphosphate into phosphatidylinositol
3,4,5-triphosphate, which binds both Akt and 3-phosphoi-
nositide-dependent protein kinase 1 (PDK1), allowing PDK1
to phosphorylate Akt.54,56 Class 1A PI3K consists of two
subunits: the catalytic subunit p110 and the regulatory sub-
unit p85. There are four isoforms of p110: p110-alpha, beta,
gamma, and sigma and three p85 isoforms: p85-alpha, beta,
and gamma. The primary direct downstream target protein
of PI3K is Akt. There are three Akt isoforms: Akt1, Akt2, and
Akt3.57 The activation of Akt causes a cascade of responses of
downstream targets that regulate cellular functions (Fig. 1).
For example, Akt regulates cell migration via Rac1 and rhoA,
increases cell survival via bcl-2, enhances angiogenesis via
VEGF, and increases cell proliferation via the activation of
mammalian target of rapamycin (mTOR).50,54
The activation of the PI3K/Akt pathway in MSCs has been
applied in both cellular therapy and tissue engineering. In
cellular therapy studies, stimulators of the pathway and the
overexpression of some major components of the pathway
have been used to induce the repair of infarcted cardiovas-
cular cells and were demonstrated to increase the efficacy of
MSCs.22,58,59 In tissue engineering studies, MSCs have been
transplanted together with various growth factors, such as
VEGF and fibroblast growth factor (FGF), to increase the
functionality of MSCs.14 However, the overexpression of key
components of the PI3K/Akt pathway has not been applied
in tissue engineering and warrants further studies.
The PI3K/Akt pathway and survival ability of MSCs
The role of the PI3K/Akt in the survival of MSCs is
evidenced by the effects of both overexpression of key
components of this pathway and chemical stimulation of
the pathway (Fig. 2). Mangi et al. overexpressed Akt1 in
MSCs to improve MSC survival after transplantation into
the heart in rats.58 The overexpression of Akt1 greatly im-
proved the ability of MSCs to treat myocardial infarction. In
Akt-overexpressing MSCs, the levels of target proteins
downstream of Akt, such as anti-apoptotic protein bcl-2,
FIG. 1. The phosphoinositide 3-kinase (PI3K)/ Protein ki-
nase B (Akt) pathway in mesenchymal stem cells (MSCs).
The activity of the PI3K/Akt pathway in MSCs can be
stimulated by growth factors or hypoxia. Activated Akt
promotes MSC proliferation, angiogenesis, survival, and
migration via downstream target proteins such as mamma-
lian target of rapamycin (mTOR), vascular endothelial
growth factor (VEGF), Bcl-2, and Rac-1. Color images avail-
able online at www.liebertpub.com/teb
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were increased, whereas the level of the pro-apoptotic
protein bax was decreased. Lim et al. extended the study to
a large animal model, showing that Akt-overexpressing
MSCs also exhibited increased efficacy in porcine myocar-
dial infarction.60
Periostin is a matricellular protein that can bind to in-
tegrin to activate the PI3K/Akt pathway.61,62 It has been
overexpressed in MSCs to increase the survival of these
cells.59 In periostin-overexpressing MSCs, the PI3K/Akt
pathway was activated, and the therapeutic efficiency was
increased. Periostin-overexpressing MSCs and the condi-
tioned medium from these cells were able to increase the
survival of cardiomyocytes under hypoxic conditions in a
coculture system.
The overexpression of bcl-2 has been shown to increase
MSC survival and increase MSC function in the treatment of
myocardial infarction.63 In a rat model of myocardial infarc-
tion established by left anterior descending ligation, MSCs
overexpressing bcl-2 were injected into damaged rat hearts.
These MSCs increased the survival of the transplanted cells
in vivo. In an in vitro experiment, bcl-2 reduced MSC apoptosis
by 32% and increased VEGF secretion by 60% under hypoxic
conditions.63 The overexpression of bcl-2 in MSCs has also
been shown to increase their ability to protect neurons.64
These gene-overexpressed MSCs may be used in tissue engi-
neering in a scaffold to increase tissue formation.
Pretreatment of MSCs with PI3K/Akt pathway stimula-
tors has been shown to increase MSC survival. Several toll-
like receptor stimulators have been used to increase MSC
functionality in tissue engineering, and the PI3K/Akt path-
way has been demonstrated to play a key role. Wang et al.
showed that lipopolysaccharide (LPS), a TLR4 ligand, in-
creased MSC survival. The pretreatment of MSCs with 1 mg/
mL of LPS protected MSCs from oxidant stress-induced ap-
optosis.65 The activation of the PI3K/Akt pathway was
demonstrated by the increased phosphorylation of Akt at Ser
473 and phosphorylatopn of nuclear factor-kappaB (NF-kB)
p65 at Ser 536. The effect of LPS was abolished in TLR4-
deleted MSCs, indicating that the LPS/TLR4/PI3K pathway
played a key role.
Stromal cell-derived factor-1 (SDF-1) has been shown to
increase MSC survival by several studies.66–68 Liu et al.
demonstrated that SDF-1 can increase the resistance of MSCs
to apoptosis induced by H2O2.
39 The pretreatment of MSCs
with SDF-1 significantly reduced apoptosis by activating the
PI3K/Akt pathway. In these cells, the Bcl-2/bax ratio was
increased, indicating a decreased level of apoptosis induced
through the mitochondrial pathway. Yin et al. showed that
addition of 0.5–2mg/ml of SDF-1 inhibited hypoxia and se-
rum deprivation-induced apoptosis of MSCs.66 The effect
was abolished by PI3K inhibitor wortmannin, indicating the
important role of the PI3K/Akt pathway in SDF-1-increased
MSC survival.
The PI3K/Akt pathway and MSC proliferation
MSCs must proliferate to be successfully applied in tissue
engineering. First, MSCs must be enriched in vitro through
cell proliferation because MSCs are rare in the bone mar-
row. MSCs only account for 0.001–0.01% of all bone mar-
row cells.5,22 Second, it could be helpful if MSCs
proliferated after transplantation. It has been shown that
the actual number of MSCs that form new tissue is far too
small.22 This could be caused by low survival rates and
proliferation. Evidence showed that less than 3% of MSCs
persist 2 weeks after transplantation.22,39 In in vitro cell
culture, many growth factors have been used to stimulate
MSC proliferation such as prostaglandin E2 (PGE2), hepatic
growth factor (HGF), FGF, tumor necrosis factor-alpha
(TNF-alpha), transforming growth factor-beta (TGF-beta),
epidermal growth factor (EGF), and insulin.69–71 All these
factors are stimulators of the PI3K/Akt pathway, indicating
the importance of the activation of the pathway in the
proliferation of MSCs.
The activation of the PI3K/Akt pathway has been dem-
onstrated to be a mediator of several factors that increase
MSC proliferation. PGE2 has been shown to increase the
proliferation of MSCs from human umbilical cord blood.70
PGE2 phosphorylates Akt, which in turn phosphorylates
GSK-3beta, leading to the accumulation of active beta-
catenin in the nucleus (Fig. 3). Beta-catenin is a transcriptional
factor that increases the expression of c-Myc to promote cell
proliferation.70 TNF-alpha can also increase MSC prolifera-
tion via the activation of downstream target proteins of the
PI3K/Akt pathway, including NF-kB and cyclin D1.72,73
FGF-beta has been extensively studied to increase MSC
proliferation and the activation of the PI3K/Akt pathway
was shown to be important for the effect.74,75 The pathway is
also involved in EGF-increased MSC proliferation.76,77 These
factors may be studied in tissue engineering apparatus for
their effects on the proliferation of MSCs and on the activity
of the PI3K/Akt pathway.
The role of the PI3K/Akt pathway in MSC proliferation
has been demonstrated by activating the pathway by mu-
tating the regulatory subunit of PI3K in MSCs. The subunit
p85a negatively regulates the catalytic subunit p110. The
introduction of p85a - / - into MSCs resulted in an increase in
FIG. 2. PI3K and the survival of MSCs. In MSCs, the ac-
tivity of the PI3K/Akt pathway is stimulated by stromal cell-
derived factor-1 (SDF-1) and lipospolysaccharide (LPS) and
by the overexpression of periostin. Activated Akt can in-
crease MSC survival by blocking bax, which is a pro-apo-
ptotic protein, and by increasing Bcl-2, which can reduce the
level of apoptosis. Color images available online at www
.liebertpub.com/teb
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the level of pAkt.78 It was observed that over a span of 10
continuous passages of cultured p85a - / - MSCs, the cell
proliferation rate was maintained, as indicated by the in-
creased number of cells and the increased formation of col-
onies. Increased cell cycling was indicated by a lower
number of cells in G1 and a greater number of cells in G2.
There were consistent changes in the proteins regulating the
cell cycle, including increased levels of the cell cycle-
promoting proteins cyclins D and E and reduced levels of the
cell cycle blockers p16 and p19.
The PI3K/Akt and MSC migration
To be able to function properly, MSCs have to move to the
appropriate place. MSCs are recruited into sites of injury by
cytokines and chemokines so that these cells can help repair
the injury.79 MSCs also move along vessels sprouting from
endothelial cells to facilitate vessel formation and mainte-
nance.80 Many studies have demonstrated that the migration
ability of MSCs affects their efficacy.81,82 Therefore, a greater
understanding of the mechanisms involved in MSCs migra-
tion will facilitate the application of these cells in tissue en-
gineering.
Cell migration is closely related to changes in the cyto-
skeleton and to the formation of movement structures. The
present theory of cell migration is summarized in several
reviews.83,84 In brief, actin plays a key role in cell move-
ment,85 although several other structural proteins are in-
volved in the cytoskeleton. During migration, cells become
asymmetrical, forming front and back ends to direct cell
movement. At the front, there are filopodia and lamellipodia.
At the back, stress fibers, which are involved in cell adhesion,
are formed or deformed to facilitate cell migration.
The PI3K/Akt pathway is well known to affect cyto-
skeleton changes in many cells, particularly in cancer cells.
p70(S6K), a downstream target of the PI3K/Akt pathway,
can regulate cytoskeleton dynamics via actin filament cross-
linking proteins (Fig. 4). The overexpression of p70(S6K) in
ovarian cancer cells promoted directional cell migration.86
p70(S6K) stimulated the rapid activation of Rac-1 and
CDC42 and their downstream effector, p21-activated kinase
(PAK1).86 Inhibition of p70(S6K) activity resulted in the
decreased expression of these proteins and in actin cyto-
skeleton reorganization. In embryonic fibroblasts, Rac-1-
null cells were defective in lamellipodia formation, cell
spreading, cell-fibronectin adhesion, and focal contact for-
mation when stimulated with platelet-derived growth fac-
tor (PDGF).87 The phosphorylation of PAK1 was reduced,
and the reconstitution of active PAK1 counteracted this ef-
fect. Girdin, a newly found actin-binding protein, is also a
substrate of Akt. The phosphorylation of girdin by Akt is
important to girdin’s function in cell migration. Girdin is
essential for the formation of stress fibers and lamellipodia
in fibroblasts and endothelial cells.88,89 The RNAi knock-
down of girdin was found to disrupt the rearrangement of
the actin cytoskeleton in vascular smooth muscle cells.90
The girdin-related migration of endothelial cells is involved
in angiogenesis.91 However, the role of girdin and its re-
lated signal pathways in MSC migration has not been
studied.
In MSCs, several PI3K/Akt stimulators have been shown
to increase MSC migration. The role of SDF-1, one such
stimulator, in MSC migration has been well studied.79 A
study has shown that SDF-1 promoted MSC migration in a
bone regeneration scaffold.92 SDF-1-increased MSC migra-
tion was mediated by the activation of the PI3K/Akt path-
way.39 Hypoxia conditioning has also been shown to
increase MSC migration via the PI3K/Akt pathway, and this
effect was abolished by the PI3K inhibitors wortmannin and
LY294002.93,94 However, the downstream target proteins of
the PI3K/Akt pathway in MSC migration is not well un-
derstood and warrant further studies.
FIG. 3. PI3K and the proliferation of MSCs. Phosphory-
lated Akt can block the p16 and p19 proteins and promote an
increase in cell cycling of MSCs via cyclin D and E. Phos-
phorylated Akt also prevents GSK-3beta from forming a
complex with beta-catenin, resulting in the accumulation of
beta-catenin. Accumulated beta-catenin can increase the ex-
pression of myc, which is known to increase cell prolifera-
tion. Akt also increases proliferation via the nuclear factor-
kappaB (NF-kB) pathway. Color images available online at
www.liebertpub.com/teb
FIG. 4. MSC migration promoted by the PI3K/Akt path-
way. PI3K can activate Akt, which in turn increases the ex-
pression of RhoA, thus changing the cytoskeleton. Akt also
phosphorylates p70S6K, which increases Rac-1 and CDC42
expression, leading to PAK1 activation and cytoskeleton
changes. PI3K also directly acts on Rac-1. Color images
available online at www.liebertpub.com/teb
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The PI3K/Akt pathway and MSC-induced
angiogenesis
Angiogenesis is necessary for the survival of new tissues
formed by tissue engineering because blood vessels are re-
quired to supply nutrients and transport out wastes. MSCs
can help vessels to grow and invade from neighboring tis-
sues by promoting the formation of tubes by endothelial
cells. MSCs can recruit pericytes and smooth muscle cells to
promote the maturation of newly formed blood vessels.80 In
addition, MSCs themselves can also differentiate into endo-
thelial cells to increase vascularization.95
Several studies have demonstrated that the activation of the
PI3K/Akt pathway increases the angiogenesis ability of MSCs.
Several stimulators of the PI3K/Akt pathway, such as SDF-1
and cobalt chloride (CoCl2), have been shown to increase an-
giogenesis. The overexpression of SDF-1 was also shown to
increase angiogenesis.26 MiR-126-overexpressing MSCs in-
creased the level of angiogenesis in an infarcted area in mice
subjected to ligation of the coronary artery by increasing the
levels of pAkt and pErk.96 The delivery of angiopoietin-1 with a
Sendai virus-based vector to MSCs increased the pAkt levels
and resulted in increased angiogenesis.97 Adrenomedullin, an
activator of the PI3K/Akt pathway, was shown to increase
angiogenesis when it was infused together with transplanted
MSCs.25 The effect of MSCs on endothelial cells with respect to
angiogenesis was also demonstrated using conditioned me-
dium from MSC cultures. This medium increased the level of
angiogenesis by increasing the level pAkt and the effect was
inhibited by a PI3K/Akt inhibitor.98
The PI3K/Akt and cytokine production of MSCs
MSCs can secrete many cytokines that regulate other cells
and facilitate tissue repair; these cytokines include VEGF,
FGF, monocyte chemoattractant protein-1, HGF, insulin-like
growth factor-I (IGF-I), SDF-1, and thrombopoietin.99–101 The
cytokines secreted by MSCs are required for MSCs to exert
their effects in infarcted heart tissue because the numbers of
surviving MSCs and differentiated cells derived from MSCs
are low.102 The secreted cytokines can promote the recruit-
ment of local cells for injury repair. The role of cytokines
secreted by MSCs as local regulators was further demon-
strated by the ability of conditioned MSC medium to ame-
liorate myocardial infarction.103 Conditioned medium from
MSC culture also increased wound healing indicated by re-
cruitment of macrophages and endothelial cells.104 It has
been shown that systemic delivery of BMSCs decreased
neuropathy and this effect was reduced by neutralizing an-
tibodies against brain-derived neurotrophic factor (BDNF),
indicating importance of MSC-secreted factors. Secreted
neuron growth factors such as nerve growth factor, BDNF,
and glial cell line-derived neurotrophic factor also facilitate
the recovery from Alzheimer’s disease, Huntington’s dis-
ease, Parkinson’s disease, multiple sclerosis, and Krabbe’s
disease.105
Evidence has shown that the MSC’s ability to secrete cyto-
kines is regulated by PI3K/Akt activity. SDF-1 has been
shown to increase the secretion of cytokines by MSCs, and this
effect is mediated by the PI3K/Akt pathway.39 The over-
expression of Akt1 in MSCs increased the gene expression of
VEGF, FGF-2, HGF, and IGF-1 and thus increased the secretion
of these cytokines.103 Akt1-induced cytokine secretion has
been linked to the increased survival of infarcted myocardial
cells. interleukin-6 and TNF-alpha can synergistically costi-
mulate MSCs to produce VEGF via the PI3K/Akt pathway.106
NF-kB, a downstream protein in the PI3K/Akt pathway, was
also shown to play an important role in the TNF-alpha-
induced production of VEGF, FGF, HGF, and IGF-1.107
These cytokines can also act on MSCs to affect their
functionalities. For example, MSCs can express HGF receptor,
c-Met.108,109 HGF-expressing MSCs have a greater ability to
repair myocardial infarction, whereas HGF-null MSCs are
unable to repair ischemic limbs.110,111 This effect of HGF was
demonstrated to be mediated by the PI3K/Akt pathway.
HGF at a concentration of 20 ng/mL promoted osteogenic
differentiation via the activation of c-Met, Akt pathway, and
the increased expression of cell cycle inhibitor p27 and oste-
ogenic-associated transcription factors Runx2 and osterix,
whereas a high concentration of HGF (100 ng/mL) promoted
proliferation and suppressed osteogenic differentiation by
activating Erk1/2 pathway and inhibiting Akt pathway.112,113
The PI3K/Akt pathway and MSC differentiation
The PI3K/Akt pathway has been shown to be important
in the differentiation of MSCs into various cell types. How-
ever, the roles of this pathway are complicated by contro-
versial effects. For example, the levels of components of the
PI3K/Akt pathway and its downstream proteins mTOR,
FOXO1, p27(kip1), and p70S6K are increased during the dif-
ferentiation of MSCs into adipocytes.114–116 The inhibition of
this pathway with the PI3K-specific inhibitor LY294002 re-
sulted in decreased adipogenesis, indicating that the PI3K/Akt
pathway plays an important role in adipogenesis.114 The acti-
vation of the downstream protein mTOR is sufficient to pro-
mote adipogenesis, and this process is inhibited by rapamycin.
It has been demonstrated that mTOR upregulates peroxisome
proliferator-activated receptor gamma and CCAAT-enhancer
binding protein alpha, two master adipogenic transcrip-
tional factors115 (Fig. 5). Further, the protein Lar (leukocyte
FIG. 5. PI3K and adipogenesis. The PI3K/Akt pathway can
regulate adipogenesis via mTOR, which can increase the
levels of peroxisome proliferator-activated receptor gamma
(PPAR-gamma) and CCAAT-enhancer binding protein alpha
(CEBP-alpha). The PI3K-specific inhibitor LY294002 and the
mTOR inhibitor rapamycin decrease the level of adipogenesis.
Color images available online at www.liebertpub.com/teb
520 CHEN ET AL.
common antigen-related tyrosine phosphatase) negatively
regulates the adipogenesis of MSCs by inhibiting the PI3K/Akt
pathway.116
IGF-I has been expressed in MSCs to increase osteogenesis
for bone repair, and the mechanism shown involved the
activation of IRS1-PI3K.106 Although IGF-1 can also activate
mitogen-activated protein kinase (MAPK) pathway, several
studies have shown that inhibition of MAPKs increases ra-
ther than decreases the rate of osteogenesis,117–120 indicating
the PI3K/Akt pathway plays the key role in IGF-1-induced
osteogenesis. TNF-alpha was shown to increase osteogenesis
by activating NF-kB in MSCs from human adipose tissue;
this induction of osteogenesis by TNF-alpha was blocked by
an NF-kB inhibitor.121 The mechanically induced activation
of Akt has also been shown to increase osteogenesis.122,123
Several studies have yielded controversial results about
the role of the PI3K/Akt pathway in adipogenesis and os-
teogenesis. Fitter et al. showed that imatinib promoted
adipogenesis by inhibiting PDGF-induced PI3K activity.124
Controversial results regarding the role of the PI3K/Akt
pathway in osteogenesis have also been presented.125–131
Studies have shown that imatinib stimulates osteogenesis
by inhibiting PDGFR/PI3K/Akt signaling in MSCs.132–134
The reason for this effect is not well understood. It is pos-
sible that PDGF induces adipogenesis via signaling path-
ways different from those involved in the stimulation
by special adipogenic medium (1 mM dexamethasone,
0.2 mM indomethacin, 0.5 mM 3-Isobutyl-1-methylxanthine,
0.01 mg/mL insulin, and 10% fetal bovine serum). It is now
known that multiple signal pathways are involved in line-
age determination. Canonical and non-canonical Wnts are
involved in determining whether MSCs differentiate into
osteocytes or adipocytes.135,136 FGF was demonstrated to
increase osteogenesis via FGFR1 and 2, which activate the
PI3K/Akt and Erk1/2 pathways.137 The role of the inter-
action of multiple signal pathways in MSC differentiation
has also been studied.138 However, no conclusive explana-
tion has been revealed by the results.
The importance of PI3K/Akt pathway in chondrogenesis
has also been demonstrated. Insulin was shown to increase
chondrogenesis via activation of PI3K/Akt pathway.139
IGF-1 also promoted chondrogenesis via the same pathway
and its downstream target protein NF-kB.140 Delta-like 1
protein, which inhibits Akt but not Erk1/2 and p38 MAPK
reduced insulin-induced chondrogenic differentiation as
demonstrated by a reduction of cartilage pellet formation
and expression of genes involved in chondrogenesis such as
aggrecan, collagen Type II, and X.139 Addition of Delta-like
1 protein into chondrogenic medium produced a dose-
dependent inhibition of chondrogenesis that was reversed
by fibronectin, an activator of the PI3K/Akt pathway.139
MSCs may also differentiate into other cells types such as
neurons, cardiomyocytes, hepatocytes, and pancreatic beta-
cells.35 However, the role of PI3K/Akt pathway in the dif-
ferentiation of these cells has not been studied well. Further
exploration of the pathway may help to promote the po-
tential use of MSCs in the regeneration of these cells.
The roles of PI3K/Akt pathway in the functionalities of
ASCs have also been studied but in a much less extent than
that of BMSCs. It has been demonstrated that stimulation of
the activity of Akt promoted the differentiation of ASCs into
adipose tissue while inhibition of the pathway by Wart-
mannin reduced adipose tissue formation.141 Hypoxia condi-
tion has been shown to increase the survival ability,
proliferation, angiogenesis, growth factor secretion, and mi-
gration of ASCs via HIF-alpha/VEGF-A/PI3K/Akt path-
way.142–146 Both neutralizing antibodies against VEGF-A and
inhibitor of PI3K may abolish the effect of hypoxia condition.
These studies indicate that the pathway may also play a key
role in ASCs in all aspects described above. More studies about
the roles of the PI3K/Akt pathway in ASCs are warranted.
The Effect of Biomaterials on the Activity of PI3K/Akt
Pathway in MSCs
Effective tissue engineering such as bone regeneration
required optimal interactions of three components including
MSC cells, biomaterials used for scaffolds, and bioactive
molecules.147–151 Biomaterials are used not only for me-
chanical support but also stimulation of MSCs. At present
many different kinds of biomaterials have been used to make
scaffolds including polymers, calcium phosphate (CaP), and
bioglass etc. Current studies in biomaterials attempt to in-
crease their capability to stimulate MSCs to form new tissues.
For the purpose, biomaterials with new properties have been
made, surface structure of biomaterials has been modified,
and growth factors have been loaded to scaffolds. Bioma-
terials-increased MSC functionalities have been associated
with the activation of the PI3K/Akt pathway as described in
the following sections.
Change of nature of biomaterials
Novel biomaterials have been made so that they have
increased capability to increase MSC functionalities. CaP
such as b-tricalcium phosphate and hydroxyapatite (HAP)
possesses good mechanical properties, biocompatibility,
and osteoconductivity, but it lacks biodegradability.12
Polymers are more popular for making scaffolds due to
their property of biodegradation. However, the disadvan-
tage of polymers is that their osteoconductivity is very low.
Woo et al. developed a novel material using a mixture of
HAP and polymer PLLA called PLLA/HAP.152 In an
in vitro culture system, this novel biomaterial has been
shown to increase MSC cell survival as indicated by DNA
content and decrease apoptosis detected by Tunel assay.
The mechanism was demonstrated that PLLA/HAP could
absorb more fibronectin and vitonectin, which increased the
activity of the PI3K/Akt as indicated by increased levels of
pAkt and its downstream target bcl-2. This study provides a
good example that manipulation of biomaterials can in-
crease MSC functionalities via the activation of PI3K/Akt
pathway. At present, many biomaterials have been studied
to increase MSC functionalities. However, the involvement
of the PI3K/Akt is not extensively studied. It will be in-
teresting to investigate how biomaterials affect MSC dif-
ferent functionalities through the PI3K/Akt and its
downstream target proteins. Our studies have shown that
CoCl2 can increase MSC proliferation and differentiation.
49
It also increased MSC secretion of VEGF and thus increased
vascularization in animal model.45 The PI3K/Akt pathway
is likely to be involved in these effects. Several studies have
shown that CoCl2 induced hypoxia, which in turn activated
the PI3K/Akt pathway to mediate CoCl2 biological ef-
fects.153–155 Further studies are warranted to characterize
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the direct effect of CoCl2 on the activity of the PI3K/Akt
pathway and its downstream target proteins in MSCs.
Modification of biomaterial surface
Modification of the surface of biomaterials has also been
used to increase MSC functionalities. Attachment of peptides
to the surface of biomaterials has been shown to increase
their stimulatory effect on MSCs.151 Several studies demon-
strated that peptide Arg-Gly-Asp (RGD) attachment in-
creased MSC survival, proliferation, and differentiation.156–160
Zhang et al. demonstrated that RGD attached poly (capro-
lactone) (PCL) increased MSC proliferation and this was
mediated by the activation of the PI3K/Akt pathway.161
RGD activated an integrin that in turn increased Akt activity.
Control of growth factor release in scaffolds
Several growth factors such as FGF, TGF-beta, and bone
morphogenetic protein-2 (BMP-2) have been loaded on
scaffold biomaterials to increase the efficacy of bone forma-
tion.15,162 BMP-2 has been incorporated into the biomaterial
surface by several methods such as indirect adsorption, af-
finity binding, or chemically conjugating.163,164 The loading
of BMP-2 in scaffold biomaterials CaP, tricalcium phosphate,
and PCL increased bone formation.165–168 Release pattern of
BMP-2 from scaffolds is recognized to be important and
scaffold geometry has been used to achieve gradient release
of BMP-2.169–172 BMP-2 is known to increase osteogenesis
via the activation of PI3K/Akt pathway.173 It will be in-
teresting to study how BMP2 and other growth factors
loaded in scaffolds and their release pattern affect the PI3K/
Akt pathway in MSCs and thus alter MSC functionalities in
tissue engineering apparatus.
Conclusions and Future directions
The bottleneck for MSCs in tissue engineering application
is that their survival ability and functionality are very low.38
This could be overcome by activating the PI3K/Akt pathway
in MSCs, which plays key roles in the functionalities of MSCs
including cell survival ability, cell proliferation, migration,
angiogenesis, cytokine production, and differentiation as
discussed above. Therefore, activation of the pathway will
increase the performance of MSCs in tissue engineering. In-
deed, several approaches have been applied to increase MSC
functionalities including overexpression of genes, addition of
growth factors, and manipulation of biomaterials.43–48 Sev-
eral studies showed that novel biomaterials, use of CoCl2,
incorporation of peptides on the surface of biomaterials, and
loading growth factors in scaffolds can increase MSC func-
tionalities.42,49 Biomaterial-increased MSC functionalities
have been associated with the activation of the PI3K/Akt
pathway.
In future, the ability of a biomaterial to activate PI3K/Akt
in MSCs in vitro system could be used for selection criteria
for the use in tissue engineering. Activation of the PI3K/Akt
pathway could indicate the effect of biomaterials on MSC
functionalities. It will be interesting to study how biomate-
rials affect the downstream target proteins of the PI3K/Akt
pathway associated with different functionalities of MSCs.
How loaded growth factors in scaffolds activate the PI3K/
Akt and its downstream targets in MSCs could be studied.
MSCs have been genetically engineered to overexpress reg-
ulatory genes to increase their functionalities in cellular
therapy. It is interesting to investigate whether biomaterials
have synergistic effect with these MSCs. Combinational ap-
plications of genetic engineered MSCs, growth factors, and
bioactive biomaterials could be an effective approach for
successful tissue regeneration.
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